The estimated Net Worth of Peter D Flynn is at least 169 千$ dollars as of 11 June 2014. Peter Flynn owns over 6,488 units of Fate Therapeutics Inc stock worth over 36,899$ and over the last 11 years Peter sold FATE stock worth over 131,904$.
Peter has made over 5 trades of the Fate Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Peter exercised 6,488 units of FATE stock worth 10,446$ on 11 June 2014.
The largest trade Peter's ever made was selling 9,793 units of Fate Therapeutics Inc stock on 1 May 2014 worth over 69,237$. On average, Peter trades about 2,951 units every 7 days since 2014. As of 11 June 2014 Peter still owns at least 9,510 units of Fate Therapeutics Inc stock.
You can see the complete history of Peter Flynn stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over 48,476,146$ worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth 162,421,037$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Associates V Lpvenrock Part...、Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of 384,496$. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth 2,678$.
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Fate Therapeutics Inc executives and other stock owners filed with the SEC include: